Clinical Trial VICCGI1173


A Phase 1 Study of Gemcitabine, Dasatinib and Erlotinib in Patients with Advanced Pancreatic Carcinoma

Principal Investigator(s)

Dana Cardin


  • Protocol No. VICCGI1173
  • Open Date: 07/31/2012
  • Staging: Phase I
  • Age Group: Adults
  • Scope: Local
  • Objective: To determine the maximum tolerated dose (also Phase II recommended dose) of the combination of gemcitabine, erlotinib and dasatinib in patients with advanced pancreatic adenocarcinoma.
  • Disease Sites: Gastrointestinal; Phase I; Pancreatic
  • Therapies: Chemotherapy - cytotoxic; Molecular Targeted Agents / Immunotherapy / Biologics
  • Drugs: Dasatinib (BMS-354825); Gemcitabine; Tarceva (OSI-774; erlotinib)
  • Participating Institutions: Vanderbilt University
  • National Clinical Trial ID: NCT01660971
  • Secondary Protocol No: NCI Protocol # 9043



Learn More

You do not have JavaScript enabled. This site works better with JavaScript turned on.